Form 4: Cocrystal Pharma Director Granted Stock Options

Cocrystal Pharma, Inc. director Fred Hassan received a grant of 16,410 non-qualified stock options with an exercise price of $1.10, vesting over time.

Summary

• Fred Hassan, a Director of Cocrystal Pharma, Inc. (COCP), was granted 16,410 non-qualified stock options.
• The options have an exercise price of $1.10 per share.
• The grant date for these options was January 9, 2026.
• The options are set to expire on January 9, 2036.
• One-half of the options will vest and become exercisable on January 9, 2027.
• The remaining half will vest and become exercisable in eight equal quarterly installments, commencing on March 31, 2027.
• Vesting is contingent upon Fred Hassan continuing to serve as a director of the Issuer on each applicable vesting date.
• The grant was made under the Issuer's 2025 Equity Incentive Plan and was approved by the Compensation Committee of the Board of Directors.
• The grant is exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3.

Sentiment

Score: 6

Explanation: The filing reports a routine compensation event for a director, which is generally neutral but can be seen as slightly positive due to the alignment of interests between management and shareholders. It does not contain information that would significantly alter the company's fundamental outlook.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The options are part of a pre-approved equity incentive plan, indicating structured compensation practices.

Negatives

• The grant introduces potential future dilution for existing shareholders if the options are exercised.

Risks

• The vesting of the options is subject to the reporting person continuing to serve as a director, meaning unvested options could be forfeited if service ceases.
• The value of the options is dependent on the future stock price exceeding the exercise price of $1.10; if the stock price remains below this, the options may not be in-the-money.

Future Outlook

The future outlook, as indicated by this filing, primarily relates to the director's continued service and the company's stock performance influencing the value and exercisability of the granted options over the next decade.

Management Comments

• The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors.
• The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement.
• The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as across public companies generally. It serves as a key component of executive and director compensation packages, aiming to align the interests of leadership with long-term shareholder value creation. The use of an equity incentive plan and approval by a compensation committee are standard corporate governance practices.

Comparison to Industry Standards

• The grant of non-qualified stock options to a director is a standard form of compensation, comparable to practices at other publicly traded companies, particularly in sectors where long-term value creation is emphasized.
• The vesting schedule, with a portion vesting after one year and the remainder quarterly, is a common structure designed to retain talent and incentivize sustained performance, similar to plans observed at peer companies in the biotech sector.
• The approval by the Compensation Committee and the exemption under Rule 16b-3 are standard governance procedures for such equity grants, aligning with best practices for executive compensation.

Corporate Governance

Related Party Transactions

• The grant of stock options to Fred Hassan, a director, constitutes a related party transaction, which is a standard form of compensation for board members.

Stakeholder Impact

• Shareholders: Potential for long-term alignment of director's interests with shareholder value, but also potential for minor future dilution upon exercise.
• Director (Fred Hassan): Receives equity-based compensation, providing an incentive for continued service and performance tied to the company's stock price.

Next Steps

• Execution of the Issuer's form of Non-Qualified Stock Option Agreement by the reporting person.
• Continued service of Fred Hassan as a director to ensure vesting of the options.

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to a director as part of their compensation package. It does not contain new information that would fundamentally alter the investment thesis for Cocrystal Pharma, Inc., thus a 'hold' recommendation is appropriate. Investors should continue to evaluate the company based on its operational performance, pipeline developments, and overall financial health.

Keywords

Cocrystal Pharma, COCP, Stock Options, Director Compensation, Equity Incentive Plan, Form 4, Fred Hassan, Non-Qualified Stock Options